Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03600441 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study of Abexinostat in Patients With Relapsed or Refractory Follicular Lymphoma

Study acronym: FORERUNNER
StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary completion date: Dec 31, 2024 to Dec 31, 2027 Completion date: Dec 31, 2025 to Dec 31, 2029v17 Show 1 more changeShow less
    • Completion date: Dec 31, 2025 to Dec 31, 2029
  2. Primary completion date: Dec 31, 2023 to Dec 31, 2024 Completion date: Dec 31, 2023 to Dec 31, 2025v16 Show 1 more changeShow less
    • Completion date: Dec 31, 2023 to Dec 31, 2025
  3. Primary and study completion dates: Dec 31, 2021 to Dec 31, 2023v15
  4. Primary completion date: Sep 1, 2020 to Dec 31, 2021 Completion date: Mar 1, 2021 to Dec 31, 2021v14 Show 1 more changeShow less
    • Completion date: Mar 1, 2021 to Dec 31, 2021
  5. Primary completion date: Sep 1, 2019 to Sep 1, 2020 Trial status: Recruiting to Active, Not Recruiting · Site details revised at 15 of 15 sitesv13 Show 2 more changesShow less
    • Trial status: Recruiting to Active, Not Recruiting
    • Site details revised at 15 of 15 sites
Show 11 earlier versionsHide 11 earlier versions
  1. Site contacts updated at 1 of 15 sitesv12
  2. Enrollment target: 51 to 139v11
  3. Study sites: 9 to 15v10
  4. Start date changed from estimate of Feb 28, 2019 to Aug 27, 2018 Site details revised at 7 of 9 sitesv9 Show 1 more changeShow less
    • Site details revised at 7 of 9 sites
  5. Study sites: 6 to 9v8
  6. Study sites: 4 to 6v7
  7. Start date: Nov 30, 2018 to Feb 28, 2019 Study sites: 2 to 4v6 Show 1 more changeShow less
    • Study sites: 2 to 4
  8. Start date: Sep 1, 2018 to Nov 30, 2018 Study sites: 1 to 2v5 Show 1 more changeShow less
    • Study sites: 1 to 2
  9. Trial status: Not Yet Recruiting to Recruiting Primary completion date: Jan 2019 to Sep 1, 2019 · Study sites: 0 to 1 · Completion date: Feb 2019 to Mar 1, 2021 · 1 morev4 Show 4 more changesShow less
    • Primary completion date: Jan 2019 to Sep 1, 2019
    • Study sites: 0 to 1
    • Completion date: Feb 2019 to Mar 1, 2021
    • Start date: Aug 2018 to Sep 1, 2018
  10. Start date: Jul 2018 to Aug 2018v3
  11. Re-verified, no change to tracked fieldsv2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study in patients with relapsed/refractory follicular lymphoma who have undergone at least 3 lines of therapy. Patients will receive abexinostat 80 mg (4 × 20 mg tablets) twice a day (BID) in a "one week on, one week off" schedule.
Trial Details
NCT Number NCT03600441
Lead Sponsor Xynomic Pharmaceuticals, Inc.
Conditions Follicular Lymphoma
Enrollment 139 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov